The US Supreme Court is set to hear one case this term that could bolster the biopharma industry’s ability to challenge US Food and Drug Administration rules and it is likely to take up another case that would undermine industry's reliance on agency decisions.
Mifepristone Ruling Casts ‘Shadow Of Uncertainty’ Over Every FDA Approval, Biopharma Industry Tells Supreme Court
As the new Supreme Court term begins, PhRMA and a host of biopharma CEOs and investors implore justices to take up mifepristone case to prevent chaos for drug development. High court will also consider a lawsuit that would reduce deference to federal rulemaking and it may consider another that would increase corporate liability under the Anti-Terrorism Act.
